Patents by Inventor Richard E. Chipkin

Richard E. Chipkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused benzazepines for treatment of Tourette's Syndrome
    Patent number: 11298361
    Abstract: The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: April 12, 2022
    Assignee: EMALEX BIOSCIENCES, INC.
    Inventors: Richard E. Chipkin, Rudolf Kwan
  • TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAM
    Publication number: 20210275540
    Abstract: The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Inventors: Richard E. Chipkin, Rudolf Kwan
  • Fused benzazepines for treatment of stuttering
    Patent number: 9949983
    Abstract: The present invention encompasses methods of treating a subject who stutters. The methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: April 24, 2018
    Assignee: Psyadon Pharmaceuticals, Inc.
    Inventor: Richard E. Chipkin
  • FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING
    Publication number: 20160271141
    Abstract: The present invention encompasses methods of treating a subject who stutters. The methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 22, 2016
    Inventor: Richard E. CHIPKIN
  • Fused Benzazepines for Treatment of Tourette's Syndrome
    Publication number: 20150164911
    Abstract: The present invention encompasses methods of treating a subject who has been diagnosed as having a tic disorder or a movement disorder. The tic disorder can be Tourette's Syndrome, and the methods can include the steps of: (a) identifying a subject in need of treatment; and (b) administering to the subject a therapeutically effective amount of a composition comprising a D1/D5 receptor antagonist, a D1/D5 receptor partial agonist, or a mixture thereof. For example, the D1/D5 receptor antagonist can be ecopipam or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, structural analog, metabolite, or polymorph thereof.
    Type: Application
    Filed: July 12, 2013
    Publication date: June 18, 2015
    Inventors: Richard E. Chipkin, Rudolf Kwan
  • Methods of treating pain and inflammation with 4,7-dimethyl-2-(4-pyridinyl)-1,2,4,-triazolo[1,5-a]pyrimidin-5(4H)-one or the pharmaceutically acceptable salts or solvates thereof
    Patent number: 4614743
    Abstract: The compound 4,7-dimethyl-2-(4-pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidin-5(4H)-one and the pharmaceutically acceptable salts thereof are analgesic and anti-inflammatory agents. Methods for preparing and using the compound and salts are described.
    Type: Grant
    Filed: December 27, 1983
    Date of Patent: September 30, 1986
    Assignee: Schering Corporation
    Inventors: Richard E. Chipkin, Joseph T. Witkowski
  • Tetrapeptides and derivatives having opiate activity
    Patent number: 4254024
    Abstract: A class of tetrapeptides having opiate activity having the formulaH-Tyr-X-Y-Zwherein X is D-amino acid radical; Y is Phe, DPhe, MePhe, DMePhe, Trp or DTrp; Z is Met-OH, Met-ol, Met(O)-ol, Met-OR, Met-NH.sub.2, MetHNR, DMet-OH, DMet-ol, DMet(O)-ol, DMet-OR, DMet-NH.sub.2, DMetNHR, Leu-OH, Leu-ol, Leu-OR, Leu-NH.sub.2, Leu-NHR, DLeu-OH, DLeu-ol, DLeu-OR, DLeu-NH.sub.2 or DLeu-NHR, and R is C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -hydroxyalkyl, are disclosed.
    Type: Grant
    Filed: October 16, 1979
    Date of Patent: March 3, 1981
    Assignee: Pennwalt Corporation
    Inventors: John M. Stewart, Dan H. Morris, Richard E. Chipkin